<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01366898</url>
  </required_header>
  <id_info>
    <org_study_id>LAL-07OLD</org_study_id>
    <nct_id>NCT01366898</nct_id>
  </id_info>
  <brief_title>Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (&gt; 55 Years)</brief_title>
  <official_title>PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (&gt; 55 Years)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol objective is providing adequate treatment and based on broad consensus in&#xD;
      elderly patients with Acute Lymphoblastic Leukemia (ALL). Apply uniform treatment that&#xD;
      enables a joint analysis of results strong enough to make conclusions on specific subgroups&#xD;
      of patients (genotypic subtypes, particularly LAL Bcr/abl positive, phenotype, or strata of&#xD;
      age or associated diseases). Provide results of a treatment to consider standard against&#xD;
      which to compare the results of phase II trials of experimental drugs that undoubtedly will&#xD;
      be activated in the coming years&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day IV for 5 days (-5 to -1).&#xD;
      Supplementary treatment: hydration minimum 2000 ml/day, allopurinol 300 mg / day, gastric&#xD;
      protection (as center), daily monitoring of blood glucose, daily monitoring of renal&#xD;
      function. Intrathecal treatment (diagnosis and prophylactic) day -5: 12 mg were administered&#xD;
      intrathecal methotrexate. The morphological study of the CSF will be defining initial CNS&#xD;
      involvement by LAL. Although it is recommended immunophenotypic study of CSF, the definition&#xD;
      of CNS involvement by LAL (and its therapeutic consequences) based on morphological&#xD;
      observation of blasts in CSF cytocentrifuge.&#xD;
&#xD;
      Remission induction:&#xD;
&#xD;
      Tolerance prephase period can be used to establish the final indication of treatment&#xD;
      (standard protocol or frail patients). Day 0 is free of treatment and is considered as +1 the&#xD;
      first day of induction. The total duration of the induction is 30 days, consists of two&#xD;
      phases (Phase I, days +1 to +14 and phase II, days +15 to +30). Mandatory testing is&#xD;
      considered counting the percentage of blasts in peripheral blood +8 day of induction, a&#xD;
      myelogram to day +14 to assess early response and a day +35 to assess the complete remission&#xD;
&#xD;
      (days +1 to +14)&#xD;
&#xD;
        -  Vincristine (VCR) 1 mg (absolute dose) IV 1 and 8.&#xD;
&#xD;
        -  Idarubicin (IDA): 10 mg (absolute dose) IV 1, 2, 8 and 9.&#xD;
&#xD;
        -  Dexamethasone (DEX): 10 mg/m2 bolus days 1 and 2 IV, 8 to 11&#xD;
&#xD;
      days +15 to +30)&#xD;
&#xD;
        -  cyclophosphamide (CFM): 300 mg / m 2 iV in 1 hour 15 to 17. (3 total doses).&#xD;
&#xD;
        -  Cytarabine (ARAC): 60 mg / m 2 iV in 1 hour 16 to 19, 23 to 26. (8 total doses).&#xD;
&#xD;
        -  Vincristine (VCR) 1 mg (absolute dose) iV 1 and 8.&#xD;
&#xD;
        -  Idarubicin (IDA): 10 mg (absolute dose) iV 1, 2, 8 and 9.&#xD;
&#xD;
        -  Dexamethasone (DEX): 10 mg/m2 bolus days 1 and 2 iV, 8 to 11&#xD;
&#xD;
      Consolidation:&#xD;
&#xD;
      Cycles 1, 3, 5 MTX: 1,000 mg/m2, IV infusion of 24 hours day 1 L-ASA. 10,000 IU / m 2 IV or&#xD;
      IM Day 2 Cycles 2, 4, 6 ARAC: 1,000 mg/m2, IV in 3 hours on days 1, 3 and 5&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2007</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of response rate</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms disease free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in terms of global survival</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasona, Idarubicine, ARA-C, Methotrexate</intervention_name>
    <arm_group_label>Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adults over 55 years diagnosed with ALL with chromosome Ph 'negative and naïve&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. L3 ALL with mature B phenotype or cytogenetic abnormalities ALL characteristics of&#xD;
             Burkitt type (t [8, 14], t [2, 8], t [8, 22]).&#xD;
&#xD;
          2. Biphenotypic acute leukemias and bilinear&#xD;
&#xD;
          3. Acute undifferentiated leukemia&#xD;
&#xD;
             The criteria for exclusion from treatment (but not patient record) any of the&#xD;
             following:&#xD;
&#xD;
          4. Patients with a history of severe and uncontrolled disease, including:&#xD;
&#xD;
               -  Coronary artery disease, valvular or hypertensive heart disease.&#xD;
&#xD;
               -  Chronic liver disease (active viral or alcoholic).&#xD;
&#xD;
               -  Chronic respiratory failure.&#xD;
&#xD;
               -  Renal failure not due to the ALL.&#xD;
&#xD;
               -  Serious neurological disorder not due to the ALL. f. Improperly controlled&#xD;
                  diabetes.&#xD;
&#xD;
          5. General condition affected (grades 3 and 4 of the WHO scale, see Appendix II), not&#xD;
             attributable to the LAL.&#xD;
&#xD;
          6. LAL chromosome Ph 'positive (must register even if you follow a specific protocol).&#xD;
&#xD;
          7. Lack of consent by the patient to use their medical records.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol and all Hospital Pethema</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Mª Ribera, Dr</last_name>
      <email>jribera@iconcologia.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://www.fundacionpethema.es/</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 2, 2011</study_first_submitted>
  <study_first_submitted_qc>June 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2011</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

